Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a biotechnology company with a market capitalization of $1.07 billion, recently executed a series of stock ...

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new ...

Millions of individuals rely on effective medications to manage diseases like cancer and diabetes. For those with chronic ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.

The only commercialized Ascentage product is olverembatinib, a drug approved in China as a treatment for certain patients with chronic myeloid leukemia (CML). This drug is a small molecule ...

Conclusion: Our results show that the addition of Ara-C in the treatment of patients with chronic-phase CML clearly improved the cytogenetic response rate and the RFS, but new modalities of ...

The data included socio-demographics, disease and treatment profile, and QoL ... ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid ...

A rare type of blood cancer called chronic myelogenous leukaemia could benefit from new research that can help identify which medicine will work best.

Accumulation of leukemic lymphocytes: Abnormal lymphocytes infiltrate the bone marrow, bloodstream, lymphatic tissues, and organs such as the spleen and liver. This infiltration disrupts normal ...

An estimated one-third of patients who require SPRYCEL ® treatment may also take gastric acid-reducing agents 1 ... PHYRAGO™ is indicated for adult patients with newly diagnosed Philadelphia ...